Evidence map›Paper›PMID 41400842›Full record

Trial reportThe Journal of infectious diseases2026

Assessment of Concordant Human Papillomavirus Infection With 9-Valent Vaccine Types Across Anogenital Sites in Young Men.

Cara J Broshkevitch, Anna R Giuliano, Joel M Palefsky, Georges Nahhas, Stephen E Goldstone, Brady Dubin, Alfred Saah, Alain Luxembourg, Christine Velicer, Joseph E Tota

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00090285 (An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00090285 phase3completednot on this map

An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2004 to 2017Enrolled4,065ConditionsCondylomata AcuminataArms(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, Comparator: placebo (unspecified)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cara J BroshkevitchDepartment of Epidemiology, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0002-5627-8250
Anna R GiulianoCenter for Immunization and Infection Research in Cancer (CIIRC), Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.ORCID 0000-0002-5440-8859
Joel M PalefskyDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-5097-3818
Georges NahhasDepartment of Epidemiology, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0001-8909-2228
Stephen E GoldstoneDepartment of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-7585-3508
Brady DubinMerck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.
Alfred SaahGlobal Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.
Alain LuxembourgVaccine Clinical Development, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.
Christine VelicerDepartment of Epidemiology, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.
Joseph E TotaDepartment of Epidemiology, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.

Funding

Merck & Co., Inc.Merck Sharp & Dohme LLC
6 · The paper itself

Abstract

backgroundThe global prevalence of and risk factors associated with same-type HPV infection across multiple anogenital sites among men has not been quantified.

methodsMen aged 16-27 years participating in a multi-country 4-valent HPV vaccine trial (NCT00090285) were assessed at baseline for prevalent HPV infection at penile/scrotal and perineal/perianal sites (heterosexual men [HM] and men who have sex with men [MSM]) and additionally at intra-anal sites (MSM). Concordant infection with 9-valent HPV (9vHPV) vaccine types (6/11/16/18/31/33/45/52/58) was defined as same-type 9vHPV infection at 2 or 3 sites.

results3363 HM and 595 MSM were included. Prevalence of concordant 9vHPV infection at 2 anogenital sites was 3.7% among HM and 9.1% among MSM, and 8.2% at 3 sites (including the intra-anal site) among MSM. HPV6 and HPV16 were most likely to occur at multiple anogenital sites in HM and MSM, with strong agreement observed between perineal/perianal and anal sites among MSM for HPV6 (Cohen's kappa, 0.78; 95% CI, .69-.87) and HPV16 (0.61; 95% CI, .50-.73).

conclusionsConcordant anogenital 9vHPV infection was more common among MSM than HM, which is consistent with evidence that MSM are at increased risk of HPV-related cancer across multiple anogenital sites. Clinical Trial Registration:  ClinicalTrials.gov, NCT00090285.

Indexed as

PapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesAdolescentAdultAnal CanalHomosexuality, MaleHumansMalePenisPerineumPrevalenceRisk FactorsScrotumYoung AdultPapillomavirus Vaccinesconcordant infectionHPV infectionHPV vaccineshuman papillomavirusmales

Identifiers

PMID41400842
PMCPMC13017587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.